Sunday - February 1, 2026
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
January 21, 2026
BOSTON, Massachusetts, Jan. 21 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer

*

In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to durable responses and improved progression free survival compared to the curr . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products